Found: 178
Select item for more details and to access through your institution.
The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial.
- Published in:
- Calcified Tissue International, 2010, v. 86, n. 5, p. 343, doi. 10.1007/s00223-010-9352-5
- By:
- Publication type:
- Article
A Forty-Year Follow-Up of the Dallas Bed Rest and Training Study: The Effect of Age on the Cardiovascular Response to Exercise in Men.
- Published in:
- Journals of Gerontology Series A: Biological Sciences & Medical Sciences, 2009, v. 64A, n. 2, p. 293, doi. 10.1093/gerona/gln025
- By:
- Publication type:
- Article
Syncope in a Middle-aged Man: A Revealing Electrocardiogram.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina.
- Published in:
- JAMA Internal Medicine, 2014, v. 174, n. 8, p. 1403, doi. 10.1001/jamainternmed.2014.2120
- By:
- Publication type:
- Article
Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 01, doi. 10.3389/fphar.2022.1020123
- By:
- Publication type:
- Article
Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes.
- Published in:
- JAMA: Journal of the American Medical Association, 2002, v. 287, n. 23, p. 3087, doi. 10.1001/jama.287.23.3087
- By:
- Publication type:
- Article
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
- Published in:
- Cardiovascular Diabetology, 2019, v. 18, n. 1, p. N.PAG, doi. 10.1186/s12933-019-0921-2
- By:
- Publication type:
- Article
Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-27941-5
- By:
- Publication type:
- Article
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter
Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes.
- Published in:
- Diabetologia, 2021, v. 64, n. 7, p. 1583, doi. 10.1007/s00125-021-05426-2
- By:
- Publication type:
- Article
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
- By:
- Publication type:
- Article
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1226, doi. 10.1007/s00125-021-05399-2
- By:
- Publication type:
- Article
Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study.
- Published in:
- Diabetologia, 2018, v. 61, n. 12, p. 2570, doi. 10.1007/s00125-018-4720-1
- By:
- Publication type:
- Article
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
- Published in:
- Diabetologia, 2018, v. 61, n. 1, p. 58, doi. 10.1007/s00125-017-4422-0
- By:
- Publication type:
- Article
Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5336, doi. 10.1111/dom.15895
- By:
- Publication type:
- Article
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
- By:
- Publication type:
- Article
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1932, doi. 10.1111/dom.15058
- By:
- Publication type:
- Article
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1453, doi. 10.1111/dom.14991
- By:
- Publication type:
- Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
- By:
- Publication type:
- Article
Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1117, doi. 10.1111/dom.14941
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1426, doi. 10.1111/dom.14352
- By:
- Publication type:
- Article
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 569, doi. 10.1111/dom.14254
- By:
- Publication type:
- Article
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 29, doi. 10.1111/dom.14179
- By:
- Publication type:
- Article
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2487, doi. 10.1111/dom.14160
- By:
- Publication type:
- Article
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1357, doi. 10.1111/dom.14041
- By:
- Publication type:
- Article
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1122, doi. 10.1111/dom.14011
- By:
- Publication type:
- Article
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2440, doi. 10.1111/dom.13825
- By:
- Publication type:
- Article
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1625, doi. 10.1111/dom.13699
- By:
- Publication type:
- Article
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1437, doi. 10.1111/dom.13677
- By:
- Publication type:
- Article
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1073, doi. 10.1111/dom.13645
- By:
- Publication type:
- Article
Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 2, p. 261, doi. 10.1111/dom.13511
- By:
- Publication type:
- Article
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2379, doi. 10.1111/dom.13377
- By:
- Publication type:
- Article
DECLARE‐TIMI 58: Participants’ baseline characteristics.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1102, doi. 10.1111/dom.13217
- By:
- Publication type:
- Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
- By:
- Publication type:
- Article
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC).
- Published in:
- European Heart Journal, 2023, v. 44, n. 39, p. 4043, doi. 10.1093/eurheartj/ehad192
- By:
- Publication type:
- Article
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials.
- Published in:
- European Heart Journal, 2023, v. 44, n. 21, p. 1890, doi. 10.1093/eurheartj/ehad171
- By:
- Publication type:
- Article
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial.
- Published in:
- European Heart Journal, 2022, v. 43, n. 31, p. 2958, doi. 10.1093/eurheartj/ehab530
- By:
- Publication type:
- Article
Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Sex differences in the relationship between C-reactive protein and body fat.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
- Published in:
- Sleep & Breathing, 2023, v. 27, n. 2, p. 669, doi. 10.1007/s11325-022-02594-2
- By:
- Publication type:
- Article
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 2, p. e2148030, doi. 10.1001/jamanetworkopen.2021.48030
- By:
- Publication type:
- Article
Recurrent pericardial effusion and tamponade after epicardial pacemaker lead placement: a case report.
- Published in:
- European Heart Journal Case Reports, 2022, v. 6, n. 4, p. 1, doi. 10.1093/ehjcr/ytac114
- By:
- Publication type:
- Article
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 15, p. 1261, doi. 10.1001/jama.2023.2854
- By:
- Publication type:
- Article
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments.
- Published in:
- European Heart Journal, 2011, v. 32, n. 15, p. 1832, doi. 10.1093/eurheartj/ehr019
- By:
- Publication type:
- Article
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.
- Published in:
- European Heart Journal, 2010, v. 31, n. 18, p. 2262, doi. 10.1093/eurheartj/ehq228
- By:
- Publication type:
- Article
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events.
- Published in:
- European Heart Journal, 2005, v. 26, n. 13, p. 1255, doi. 10.1093/eurheartj/ehi230
- By:
- Publication type:
- Article
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
- Published in:
- Cardiovascular Diabetology, 2018, v. 17, p. 1, doi. 10.1186/s12933-018-0682-3
- By:
- Publication type:
- Article